The elastomeric infusion pumps market is likely to advance at an above-average growth rate of ~9 percent during 2019-2030, as market players continue to push the envelope of the landscape with an innovative approach. The rapid rise in the sales of elastomeric infusion pumps is highly attributable to the growing importance of better pain management systems to ensure the overall wellbeing of a patient. In addition, rising number of surgeries in hospitals, ambulatory care centers, and outpatient care centers, is likely to upkeep the demand for elastomeric infusion pumps, owing to the post-operative care required when patients get an early discharge.

The study also reports the development of advanced elastomeric infusion pumps to monitor patient safety by enhancing the precision of the dose. In addition, favorable reimbursement scenarios in the homecare infusion therapy are anticipated to catapult demand for elastomeric infusion pumps. However, market players need to develop products within the well-defined limits of regulations to avoid the instances of the product recall.

Error in the Precision of Elastomeric Infusion Pumps to Drive Product Recall Instances

According to the U.S. FDA, ~3% of the events linked with the application of elastomeric infusion pumps came to light that reported the adverse effect on the human body and some even lead to injuries and caused deaths. Such incidences have had a significant impact on the clearance procedure of the product, which leads to high market time, on account of the stringent quality filters set by the FDA. Beside failures to maintain the accuracy levels of elastomeric infusion pumps, market players witness product recalls on account of design deficiencies. Since elastomeric infusion pumps encounter software issues, false alarms, battery failure, electric shocks, and sparks, central authorities have levelled up the notch of quality checks to ensure human safety.

Given a large number of product recalls, acquisition and merger activities are seen in the elastomeric infusion pumps market. For instance, Pfizer announced the acquisition of Hospira, as the latter had long-suffered from high instances of product recalls.

‘User-friendliness’ and ‘Lightweight’ to Remain Key Selling Proposition for Elastomeric Infusion Pumps

The study also points towards the growing focus of market players towards the development of the user-friendly and light weighted elastomeric infusion pumps. In addition, since high-cost can be a barrier to the growth of the elastomeric infusion pumps, market players are offering products at an attractive rate to push their products forward in the sales channel.

Another crucial aspect that manufacturers have been focusing on is towards the development of products with multiple applications. For instance, a market player – Baxter – positioned its product for chelation therapy and chemotherapy, while another player

Request For Report Sample:

leveraged the niche-positioning strategy for penetrating its product – ON-Q Pain Relief System – for the management of postoperative pain and chemotherapy. Currently hospitals are the key consumer of elastomeric infusion pumps, on account of the growing number of hospitalized patients; however, in the future, ambulatory care centers and outpatient centers are likely to grow in terms of prominence in the elastomeric infusion pumps market.

Leave a comment

Your email address will not be published. Required fields are marked *